CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.
10.1007/s11684-021-0904-z
- Author:
Jian-Qing MI
1
;
Jie XU
1
;
Jianfeng ZHOU
2
;
Weili ZHAO
1
;
Zhu CHEN
1
;
J Joseph MELENHORST
3
;
Saijuan CHEN
4
Author Information
1. State Key Laboratory of Medical Genomics, Shanghai Institute of Haematology, National Research Centre for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
2. Immunotherapy Research Centre for Hematologic Diseases of Hubei Province, Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
3. Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. jos.melenhorst@pennmedicine.upenn.edu.
4. State Key Laboratory of Medical Genomics, Shanghai Institute of Haematology, National Research Centre for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. sjchen@stn.sh.cn.
- Publication Type:Review
- Keywords:
CAR T cells;
hematological malignancies;
review
- MeSH:
Hematologic Neoplasms/therapy*;
Humans;
Immunotherapy/adverse effects*;
Neoplasms;
Receptors, Chimeric Antigen;
T-Lymphocytes
- From:
Frontiers of Medicine
2021;15(6):783-804
- CountryChina
- Language:English
-
Abstract:
The current standard of care in hematological malignancies has brought considerable clinical benefits to patients. However, important bottlenecks still limit optimal achievements following a current medical practice. The genetic complexity of the diseases and the heterogeneity of tumor clones cause difficulty in ensuring long-term efficacy of conventional treatments for most hematological disorders. Consequently, new treatment strategies are necessary to improve clinical outcomes. Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematological malignancies. In this review, through a representative case study, we summarize the current experience of CAR T-cell therapy, the management of common side effects, the causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell therapy.
